Leo Pharma’s tralokinumab meets key endpoints in phase 3 atopic dermatitis trials

The overall adverse event rate was comparable between tralokinumab and placebo during the trials, said the company. Tralokinumab is an investigational and fully human monoclonal antibody, which neutralises

The post Leo Pharma’s tralokinumab meets key endpoints in phase 3 atopic dermatitis trials appeared first on Pharmaceutical Business review.

Dermira secures FDA fast track status for lebrikizumab in atopic dermatitis

According to the US biopharma company, lebrikizumab is a monoclonal antibody that can bind with very high affinity with the Interleukin 13 (IL-13) cykotine. Through this mechanism, the

The post Dermira secures FDA fast track status for lebrikizumab in atopic dermatitis appeared first on Pharmaceutical Business review.

Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo

Vedanta also announced the formation of its Immuno-Oncology Scientific Advisory Board (SAB), which is comprised of experts in immunology, immuno-oncology and the microbiome, to support the planned clinical

The post Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo appeared first on Pharmaceutical Business review.

Retrogenix and Resonant Therapeutics announce strategic alliance to identify targets of anti-tumour antibodies

Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors. By recapitulating

The post Retrogenix and Resonant Therapeutics announce strategic alliance to identify targets of anti-tumour antibodies appeared first on Pharmaceutical Business review.

Amneal to buy generic pharmaceuticals provider AvKAR for $340m

Under the deal, Amneal will acquire a 65.1% stake in AvKARE and its related affiliate conducting business as R&S Northeast. AvKARE is a private label provider of generic

The post Amneal to buy generic pharmaceuticals provider AvKAR for $340m appeared first on Pharmaceutical Business review.

Sanofi to acquire Synthorx for $2.5bn to strengthen immuno-oncology pipeline

Headquartered in California, Synthorx is focused on developing therapies for cancer and autoimmune disorders. Sanofi is offering to buy the biotechnology company at $68 per share. THOR-707, the

The post Sanofi to acquire Synthorx for $2.5bn to strengthen immuno-oncology pipeline appeared first on Pharmaceutical Business review.

Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

These analyses are from a readout of a 15-year post-marketing study that add to and complement the rigor of the Kymriah pivotal trials with evidence of the Kymriah

The post Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting appeared first on Pharmaceutical Business review.

Incheon City envisions biotech Mecca by developing Songdo Global Biotech Cluster

Aiming to attract global advanced biotechnology companies and research institutions, the City authorities will expand the industrial complex by adding the 11th Songdo industrial block with space of

The post Incheon City envisions biotech Mecca by developing Songdo Global Biotech Cluster appeared first on Pharmaceutical Business review.

Merck to buy biopharmaceutical firm ArQule for $2.7bn

ArQule is involved in the research and development of targeted therapeutics for the treatment of cancers and certain rare diseases. The company’s clinical-stage pipeline consists of four drug

The post Merck to buy biopharmaceutical firm ArQule for $2.7bn appeared first on Pharmaceutical Business review.

XBiotech to sell anti- IL-1⍺ antibody bermekimab to Janssen in $1.3bn deal

According to XBiotech, bermekimab has been designed to neutralise interleukin-1 alpha (IL-1⍺), which is known for promoting disease-causing inflammation in a wide variety of medical conditions. As per

The post XBiotech to sell anti- IL-1⍺ antibody bermekimab to Janssen in $1.3bn deal appeared first on Pharmaceutical Business review.